https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
5%, and 71.5% after 12, and 50.0%, 52.7% and 75.7% after 24months; p = 0.001) and to allow an interval extension to ≥ 12weeks (28.6%, 34.2%, and 53.3% after 12, and 34.2%, 47.7%, and 41.7% after 24months; p = 0.001). The portion of eyes achieving disease stability regressed in the second year, whereas the portion of eyes under a ≥ 12-week interval increased. This discrepancy may reflect the challenges in balancing between under-treatment and a reduced treatment burden. The portion of eyes achieving disease stabili
Like
Comment
Share
